ClinicalTrials.gg
CompletedNCT00076076Updated Dec 2, 2016

The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)

A Phase 3 interventional study of Roflumilast in Asthma, sponsored by AstraZeneca. Completed at 41 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-02.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
822
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing roflumilast in Asthma — none open to participants now, none under way, none of them phase 3. Roflumilast · Asthma.

Enrollment
2nd of 10
822 · median 300
Started
2003
with 2 others
Phase 3
5 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
8 of 10
AstraZeneca

Among the 10 studies testing roflumilast in Asthma, this one is the 2nd largest by enrollment, is one of 3 that started in 2003, is one of 5 in phase 3, and was the 2nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 10 studies testing roflumilast in Asthma is open now. The open studies under Asthma, anywhere →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing roflumilast in Asthma as a file.
02

Study summary

The purpose of this study is to confirm the dose of roflumilast to be used for asthma management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on pulmonary function and asthma symptoms.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Roflumilast
  • Asthma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Diagnosis of persistent chronic bronchial asthma
  • Baseline lung function within specified parameters
  • No change in asthma treatment during the last 4 weeks prior to start of baseline period
  • Stable clinical state
  • Except for asthma, in good health
  • Non-smokers or ex-smokers

Main Exclusion Criteria:

  • Poorly controlled asthma
  • Diagnosis of chronic pulmonary disease and/or other relevant lung diseases
  • Patients using continuously (more than 3 days per week) > 8 puffs/day rescue medication
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
822 participants

Interventions

06

What researchers measure

Primary outcomes

  1. change in lung function.

Secondary outcomes

  1. change in morning PEF

  2. asthma symptom score

  3. rescue medication

  4. time to withdrawal due to worsening asthma.

07

Study locations

41 sites
  • ALTANA Pharma
    Cities in Alabama, Alabama, United States
  • ALTANA Pharma
    Cities in Arizona, Arizona, United States
  • ALTANA Pharma
    Cities in Arkansas, Arkansas, United States
  • ALTANA Pharma
    Cities in California, California, United States
  • ALTANA Pharma
    Cities in Colorado, Colorado, United States
  • ALTANA Pharma
    Cities in Connecticut, Connecticut, United States
  • ALTANA Pharma
    Cities in Delaware, Delaware, United States
  • ALTANA Pharma
    Cities in Florida, Florida, United States
  • ALTANA Pharma
    Cities in Georgia, Georgia, United States
  • ALTANA Pharma
    Cities in Illinois, Illinois, United States
  • ALTANA Pharma
    Cities in Indiana, Indiana, United States
  • ALTANA Pharma
    Cities in Kansas, Kansas, United States
  • ALTANA Pharma
    Cities in Kentucky, Kentucky, United States
  • ALTANA Pharma
    Cities in Louisiana, Louisiana, United States
  • ALTANA Pharma
    Cities in Maine, Maine, United States
  • ALTANA Pharma
    Cities in Maryland, Maryland, United States
  • ALTANA Pharma
    Cities in Massachusetts, Massachusetts, United States
  • ALTANA Pharma
    Cities in Michigan, Michigan, United States
  • ALTANA Pharma
    Cities in Minnesota, Minnesota, United States
  • ALTANA Pharma
    Cities in Missouri, Missouri, United States
  • ALTANA Pharma
    Cities in Montana, Montana, United States
  • ALTANA Pharma
    Cities in Nebraska, Nebraska, United States
  • ALTANA Pharma
    Cities in Nevada, Nevada, United States
  • ALTANA Pharma
    Cities in New Jersey, New Jersey, United States
  • ALTANA Pharma
    Cities in New York, New York, United States
  • ALTANA Pharma
    Cities in North Carolina, North Carolina, United States
  • ALTANA Pharma
    Cities in Ohio, Ohio, United States
  • ALTANA Pharma
    Cities in Oklahoma, Oklahoma, United States
  • ALTANA Pharma
    Cities in Oregon, Oregon, United States
  • ALTANA Pharma
    Cities in Pennsylvania, Pennsylvania, United States
  • ALTANA Pharma
    Cities in Rhode Island, Rhode Island, United States
  • ALTANA Pharma
    Cities in South Carolina, South Carolina, United States
  • ALTANA Pharma
    Cities in Tennessee, Tennessee, United States
  • ALTANA Pharma
    Cities in Texas, Texas, United States
  • ALTANA Pharma
    Cities in Utah, Utah, United States
  • ALTANA Pharma
    Cities in Vermont, Vermont, United States
  • ALTANA Pharma
    Cities in Virginia, Virginia, United States
  • ALTANA Pharma
    Cities in Washington, Washington, United States
  • ALTANA Pharma
    Cities in West Virginia, West Virginia, United States
  • ALTANA Pharma
    Cities in Russia, Russian Federation
  • ALTANA Pharma
    Cities in the Ukraine, Ukraine
08

References and documents

Publications

  • Chervinsky P, Meltzer EO, Busse W, Ohta K, Bardin P, Bredenbroker D, Bateman ED. Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies. Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S28-34. doi: 10.1016/j.pupt.2015.11.003. Epub 2015 Nov 22. PubMed 26612545 ↗
  • Meltzer EO, Chervinsky P, Busse W, Ohta K, Bardin P, Bredenbroker D, Bateman ED. Roflumilast for asthma: Efficacy findings in placebo-controlled studies. Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S20-7. doi: 10.1016/j.pupt.2015.10.006. Epub 2015 Oct 21. PubMed 26498386 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003 and a completion of Jun 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2004
First posted
Jan 15, 2004
Start
Dec 2003
CompletionActual
Jun 2005
Last update
Dec 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00076076
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 15, 2004
Start date
Dec 2003
Completion
Jun 2005
Last update
Dec 2, 2016

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion